Rahul Gupta

Opinion author

Rahul Gupta, MD, MPH, MBA, is president of GATC Health, where he leads the company’s work applying AI and multiomics to accelerate drug discovery and development. From 2021 to 2025, he served as director of the White House Office of National Drug Control Policy, the first physician to hold this Cabinet-level role. In that position, he directed a $44 billion national strategy and advanced innovative approaches to addressing the overdose crisis. His career spans medicine, public health and biotechnology, making him a trusted leader at the intersection of science, policy, and innovation.

AI robotic head gazes at hand holding scales on dark blue background. Ethical decision-making, fairness, and balance in artificial intelligence concept. Low polygonal abstract vector illustration

Opinion

FDA alignment is critical to serving the rare disease community. AI can help

The FDA has introduced models intended to accelerate rare disease drug development, but recent reversals of guidance from the agency speak to a lack of clarity in its implementation. AI can help focus this process.

May 18, 2026

4 min read

Rahul Gupta